SEC Form SC 13D filed by Jeffs' Brands Ltd

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. )*

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

* There were 9,177,100 ordinary shares, no par value per share, of Jeffs’ Brands Ltd, an Israel corporation, issued and outstanding as of June 30, 2024, based upon the information disclosed in the Company’s Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on September 30, 2024. As of the filing of this Schedule 13D, the Reporting Person may be deemed to beneficially own 1,720,002 Ordinary Shares, or 18.7% of the Ordinary Shares issued and outstanding as of such date.

Item 1. Security and Issuer.

This Schedule 13D relates to the ordinary shares, no par value per share (the “Ordinary Shares”), of Jeffs’ Brands Ltd, an Israel corporation (the “Company”). The address of the principal executive offices of the Company is 7 Mezada Street, Bnei Brak, Israel 5126112.

Item 2. Identity and Background.

(a) This statement is being filed by Jeffrey J. Conroy (the “Reporting Person”).

(b) The principal business address for the Reporting Person is 7 Mayflower Drive, Basking Ridge, New Jersey 07920.

(c) The principal business of the Reporting Person is investing in securities, healthcare data analytics, rare disease forecasting, and technological consulting. The Reporting Person serves as the Founder and Managing Principal of Global HC Analytics LLC, a consulting firm focused on life sciences and healthcare data analytics, with a principal place of business of 7 Mayflower Drive, Basking Ridge, New Jersey 07920.

(d) During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) The Reporting Person is a citizen of the United States of America.

Item 3. Source and Amount of Funds or Other Consideration.

The 1,720,002 Ordinary Shares reported in this Schedule 13D were purchased by the Reporting Person with personal funds. The net aggregate purchase price of the Ordinary Shares was $557,962.06.

Item 4. Purpose of Transaction.

The 1,720,002 Ordinary Shares reported in this Schedule 13D were acquired for investment purposes in the ordinary course of business of the Reporting Person. The Reporting Person acquired beneficial ownership of the Ordinary Shares in the belief that the shares represented an attractive investment opportunity.

The Reporting Person expects to engage in, discussions with members of management and the board of directors of the Company (the “Board”), other current or prospective shareholders, industry analysts, existing or potential strategic partners or competitors, investment and financing professionals, sources of credit and other third parties regarding a variety of matters relating to the Company, which may include, among other things, the Company’s business, management, assets, operations, capital structure and allocation, corporate governance, Board composition and strategic alternatives and direction, and may take other steps seeking to bring about changes to increase shareholder value as well as pursue other plans or proposals that relate to or could result in any of the matters set forth in clauses (a)-(j) of Item 4 of Schedule 13D.

The Reporting Person expects to review from time to time his investment in the Company and may, depending on the market and other conditions: (i) purchase Ordinary Shares, options or related derivatives in the open market, in privately negotiated transactions or otherwise; (ii) sell all or a portion of any Ordinary Shares, options or related derivatives now beneficially owned or hereafter acquired by him; and (iii) engage in other plans or proposals as the Reporting Person may deem appropriate under the circumstances, including plans or proposals which may relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D. The Reporting Person may engage in communications with members of management and the Board and may engage in communications with, among others, the Company’s shareholders and other potential investors, potential strategic partners, financial advisors and other industry participants, regarding such matters.

Except as set forth above, the Reporting Person does not have any plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D. The Reporting Person may, at any time and from time to time, review or reconsider his position and/or change his purpose and/or formulate plans or proposals with respect thereto.

Item 5. Interest in Securities of the Issuer.

There were 9,177,100 Ordinary Shares of the Company issued and outstanding as of June 30, 2024, based upon the information disclosed in the Company’s Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on September 30, 2024. As of the filing date of this Schedule 13D (the “Filing Date”), the Reporting Person may be deemed to beneficially own 1,720,002 Ordinary Shares, or 18.7% of the Ordinary Shares deemed issued and outstanding as of such date.

The transactions in the Ordinary Shares of the Company by the Reporting Person during the sixty (60) days prior to September 19, 2024, and from September 19, 2024 to the Filing Date are set forth on Schedule A attached hereto and are incorporated herein by reference.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

There are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Person and between such person any other person with respect to any securities of the Company, including, but not limited to, transfer or voting of any of such securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss or the giving or withholding of proxies.

Item 7. Materials to be Filed as Exhibits.

Not applicable.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Attention: Intentional misstatements or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001).

SCHEDULE A

The following table details the transactions by the Reporting Person in Ordinary Shares of the Company during the period commencing sixty (60) days prior to September 19, 2024.

The following table details the transactions by the Reporting Person in Ordinary Shares of the Company during the period commencing September 19, 2024 through the Filing Date.

Explanation of responses: